Press release
Non-Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Pipeline Analysis
Download Sample
Access Report Overview: https://www.psmarketresearch.com/market-analysis/non-alcoholic-fatty-liver-disease-therapeutics-pipeline-analysis
The complications associated with NAFLD are liver failure, cardiovascular disease, and liver cancer. The symptoms observed in patients with NAFLD are nausea, loss of appetite, yellowing of skin and eyes, swelling of legs (leg edema), itching, and abdominal pain. Zydus Discovery DMCC is in the process of developing saroglitazar as a peroxisome proliferator-activated receptor alpha agonist for the treatment of NAFLD. University of California, San Diego is in the process of developing aramchol as a ATP binding cassette transporter I stimulant for the treatment of NAFLD. Some of the companies having the pipeline of NAFLD include AstraZeneca plc, Kowa Company, Ltd., Viking Therapeutics, Inc., and others.
Download Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/non-alcoholic-fatty-liver-disease-therapeutics-pipeline-analysis/report-sample
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=non-alcoholic-fatty-liver-disease-therapeutics-pipeline-analysis
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Browse more : https://www.psmarketresearch.com/industry-report/pharmaceuticals
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Pipeline Analysis here
News-ID: 824172 • Views: …
More Releases from P&S Market Research
Smart Cities Market Size, Revenue, Technology, Competitive Analysis, Growth Driv …
The global smart cities market is growing at a CAGR above 20% during 2018 - 2023 and will reach $2578.0 billion by 2023. Due to significant growth in automation technologies such as internet of things (IoT) and adoption of cloud based technologies, the global smart cities market is gaining huge traction. In addition, effective city asset management for public welfare, substantial operational cost savings, and automated public data generation applications…
Global Sports Food Market Expected to Witness 9.2% CAGR During 2016 – 2022
The global sports food market is expected to grow at a CAGR of 9.2% in terms of value during 2016 - 2022. Among the various types, the energy bars segment accounted for the largest share (71.5%) in the global sports food market in 2015.
Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/sports-food-market/report-sample
The manufacturers are trying to bring about products with the best blend of taste and healthy ingredients. They have started to…
Sports Nutrition Market by Type, Distribution Channel, Region, Growth and Demand …
The global sports nutrition market is expected to grow at a CAGR of 8.4% in terms of value during 2016 - 2022. Among the various types, the sports drinks segment accounted for largest share (61.4%) in the global sports nutrition market in 2015.
Request to Get the Sample Report@ https://www.psmarketresearch.com/market-analysis/sports-nutrition-market/report-sample
The increasing health concerns, such as obesity and awareness of physical appearances among all consumers groups is driving the demand for sports…
Orthopedic Trauma Devices Market Supply Chain Trends Mapping the Latest Technolo …
The global orthopedic trauma devices market is growing due to the increasing frequency of fractures, along with the growth of aging population. The advantageous features posed by orthopedic trauma devices, such as internal and external fixators to set a fracture, and in repositioning of bone fragments into their normal alignment are also driving the growth of the market worldwide. Furthermore, the internal fixators have reduced the hospital stays, reduced the…
More Releases for NAFLD
Non-Alcoholic Fatty Liver Disease (NAFLD) Market Detailed Industry Report Analys …
Introduction
Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as one of the most pressing global health challenges of the 21st century. Closely linked to the growing prevalence of obesity, type 2 diabetes, and metabolic syndrome, NAFLD is now the most common liver disorder worldwide. It ranges from simple fat accumulation in the liver (steatosis) to the more severe inflammatory stage known as Non-Alcoholic Steatohepatitis (NASH), which can progress to fibrosis, cirrhosis,…
Non-Alcoholic Fatty Liver Disease (NAFLD) Market to Rise at 5.98% CAGR, Reaching …
BREAKING: The Non-Alcoholic Fatty Liver Disease NAFLD market is positioned to become the #1 game-changing force in the global Healthcare sector by 2035, creating unprecedented growth opportunities for manufacturers, technology providers, enterprise clients, solution developers and strategic investors worldwide.
This exclusive deep-dive report delivers comprehensive analysis of the rapidly evolving Non-Alcoholic Fatty Liver Disease NAFLD industry, uncovering breakthrough technological advancements, critical market milestones and transformative future projections. It explores the revolutionary…
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA App …
Non Alcoholic Fatty Liver Disease (NAFLD) companies are Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Terns, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others.
(Albany, United States) As per DelveInsight's assessment, globally, Non Alcoholic Fatty Liver…
Non Alcoholic Fatty Liver Disease (NAFLD) Market to Witness Growth by 2032, Esti …
DelveInsight's "Non Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Non Alcoholic Fatty Liver Disease (NAFLD), historical and forecasted epidemiology as well as the Non Alcoholic Fatty Liver Disease (NAFLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Non Alcoholic Fatty Liver Disease (NAFLD) market report provides current treatment practices, emerging drugs,…
Panthera leads the way in the UK with specialist research sites for NASH and NAF …
With access to leading hepatologists, biopsy theatres, fibroscans at specialist sites and ongoing mass screening programmes Panthera can help pharma and CROs find a treatment for this increasingly common, progressive, and life-threatening diseases. Non-Alcoholic steatohepatitis NASH and Non-Alcoholic Fatty liver Disease NAFLD have no approved medical treatments to treat these inflammatory conditions.
Panthera is already involved with two trials with several more in the pipeline.
There are over a thousand studies* underway…
New Drugs for Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato …
Researchmoz added Most up-to-date research on "Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018" to its huge collection of research reports.
This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and also features data for dormant and discontinued…
